Not yet filed. No Q3 2026 Form 13F from OrbiMed Advisors has been detected on SEC EDGAR yet. The deadline for the quarter ended Sep 30, 2026 is Monday, Nov 16, 2026.
From the fund's 2026 Q2 Form 13F (filed Aug 14, 2026) — the latest quarter fully processed on this site.
| Stock | Shares | Portfolio weight |
|---|---|---|
| EWTX · Edgewise Therapeutics, Inc. | 15,518,492 | 11.68% |
| ELVN · ENLIVEN THERAPEUTICS INC | 6,776,632 | 6.37% |
| LLY · ELI LILLY & Co | 257,900 | 5.73% |
| MBX · MBX BIOSCIENCES INC | 3,428,736 | 3.51% |
| SVA · SINOVAC BIOTECH LTD | 2,718,735 | 3.42% |
| AZN · ASTRAZENECA PLC | 915,700 | 3.17% |
| GPCR · STRUCTURE THERAPEUTICS INC | 2,209,400 | 2.20% |
| SION · Sionna Therapeutics, Inc. | 2,555,877 | 2.08% |
| CRVS · CORVUS PHARMACEUTICALS INC | 7,165,006 | 1.98% |
| AVBP · ArriVent BioPharma, Inc. | 3,027,328 | 1.95% |
Largest increase 2026 Q1 → 2026 Q2: SVRA (+523.6% of shares). New position in 2026 Q2: UNH (1.24% of the portfolio). Largest trim 2026 Q1 → 2026 Q2: ALNY (-85.7% of shares). Exited in 2026 Q2: ADCT, ALHC, AMGN and 18 more.
Full record: OrbiMed Advisors fund page · manager profile & 13F-clone record · Q3 2026 season tracker.
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.